Literature DB >> 25594145

Optimal timing for drainage of infected lymphocysts after lymphadenectomy for gynecologic cancer.

Kosuke Hiramatsu1, Eiji Kobayashi, Yutaka Ueda, Tomomi Egawa-Takata, Shinya Matsuzaki, Toshihiro Kimura, Kenjiro Sawada, Kiyoshi Yoshino, Masami Fujita, Tadashi Kimura.   

Abstract

BACKGROUND: A lymphocyst (lymphocele) is a common complication of lymphadenectomy, which is a widely used surgical method for gynecologic cancers. In cases of infected lymphocysts, therapeutic strategies, including the timing and duration of antibiotics administration and cyst drainage, may vary depending on the physician. The aim of this study was to determine the optimal timing for drainage of lymphocysts infected with bacteria resistant to antibiotic treatment.
MATERIALS AND METHODS: Clinical data for 1175 patients who underwent a lymphadenectomy as part of surgery for a gynecologic malignancy between April 2000 and August 2012 at Osaka University Hospital, Osaka, Japan, were analyzed.
RESULTS: Of the 282 patients who developed a lymphocyst (24%), 35 with infected lymphocysts (12%) were analyzed. Lymphocyst infection was not associated with tumor origin, type of hysterectomy, or region of lymphadenectomy (P = 0.81, P = 0.59, and P = 0.86, respectively). The total treatment period of cases treated only with antibiotics tended to be shorter than that of cases treated with combined antibiotics and drainage, but the difference was not significant (P = 0.061). However, for severe cases which needed drainage, initiating the drainage by day 5 significantly shortened the total treatment period compared with cases started on or after day 6 (P = 0.042).
CONCLUSIONS: The appropriate time point for initiating lymphocyst drainage has been difficult to determine. The present study implies that for severe lymphocyst infections, where drainage is required in addition to antibiotics, the earlier the drainage is performed, the shorter the treatment period is. Further studies may be required to decide other optimal treatment strategies for infected lymphocysts.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25594145     DOI: 10.1097/IGC.0000000000000353

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

1.  Microbiological evaluation of infected pelvic lymphocele after robotic prostatectomy: potential predictors for culture positivity and selection of the best empirical antimicrobial therapy.

Authors:  Alaa Hamada; Catalina Hwang; Jorge Fleisher; Ingolf Tuerk
Journal:  Int Urol Nephrol       Date:  2017-04-24       Impact factor: 2.370

2.  Profiling of the Causative Bacteria in Infected Lymphocysts after Lymphadenectomy for Gynecologic Cancer by Pyrosequencing the 16S Ribosomal RNA Gene Using Next-Generation Sequencing Technology.

Authors:  Yuya Nogami; Kouji Banno; Masataka Adachi; Haruko Kunitomi; Yusuke Kobayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  Infect Dis Obstet Gynecol       Date:  2019-02-21

3.  Risk factors, microbiology and management of infected lymphocyst after lymphadenectomy for gynecologic malignancies.

Authors:  Xuegong Ma; Yingmei Wang; Aiping Fan; Mengting Dong; Xin Zhao; Xuhong Zhang; Fengxia Xue
Journal:  Arch Gynecol Obstet       Date:  2018-09-29       Impact factor: 2.344

4.  Comparison of Postoperative Benign Pelvic Cysts Occurred after Gynecologic or Gyne-oncologic Surgery Treated with Percutaneous Transcatheteric Sclerosant Alcohol Therapy.

Authors:  Cihan Comba; Aysun Erbahceci Salik; Gokhan Demirayak; Sakir Volkan Erdogan; Filiz Sacan; Isa Aykut Ozdemir
Journal:  Gynecol Minim Invasive Ther       Date:  2020-10-15

5.  Nomogram predicting risk of lymphocele in gynecologic cancer patients undergoing pelvic lymph node dissection.

Authors:  Baraem Yoo; Hyojeong Ahn; Miseon Kim; Dong Hoon Suh; Kidong Kim; Jae Hong No; Yong Beom Kim
Journal:  Obstet Gynecol Sci       Date:  2017-09-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.